Sciwind Biosciences Completes $70 Million Series C Financing And Expands Leadership Team To Advance Metabolic Disease Pipeline

Oct 12, 2021•almost 4 years ago

Amount Raised

$70 Million

Round Type

series c

Hangzhou

Description

Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease, today announced the closing of an $70 million Series C financing. The financing round was co-led by IDG Capital, Loyal Valley Capital and LYFE Capital. Sciwind plans to use the proceeds to advance clinical development of its proprietary GLP-1 receptor agonism candidates and anticipates the following development milestones from the three lead programs:

Company Information

Company

Sciwind Biosciences

Location

Hangzhou, Zhejiang, China

About

Sciwind Biosciences is a clinical stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic diseases. Its product pipeline consists of potentially first-in-class and best-in-class drug candidates. Sciwind also developed multiple proprietary technologies, including oral peptide and inhaled protein therapeutics delivery platforms and has identified multiple drug candidates based on these core platform technologies. For more information, visit www.sciwindbio.com.

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech